We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Teligent Inc | NASDAQ:TLGT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.1735 | 0.1721 | 0.1744 | 0 | 01:00:00 |
From May 2019 to May 2024
BUENA, N.J., Oct. 4, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:30 pm ET on Tuesday, October 29, 2013 to discuss 3rd quarter 2013 results.
(Logo: http://photos.prnewswire.com/prnh/20130827/MM70487LOGO)
The Company invites you to listen to the call by dialing 1-877-415-3182. International participants should call 1-857-244-7325. The passcode for the conference call is 58610371.
This call is being webcast by Thomson and can be accessed at IGI's website at www.igilabs.com.
The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents (www.streetevents.com), a password-protected event management site.
About IGI Laboratories, Inc.
IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.
SOURCE IGI Laboratories, Inc.
Copyright 2013 PR Newswire
1 Year Teligent Chart |
1 Month Teligent Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
